{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.07","upperLimit":"17.05","value":"3.83"},{"comment":"Insufficient number of events to calculate upper limit of the CI using the K-M method.","groupId":"OG001","lowerLimit":"1.87","upperLimit":"NA","value":"3.91"},{"comment":"Insufficient number of events to calculate upper limit of the CI using the K-M method.","groupId":"OG002","lowerLimit":"2.04","upperLimit":"NA","value":"9.07"},{"groupId":"OG003","lowerLimit":"17.97","upperLimit":"17.97","value":"17.97"},{"groupId":"OG004","lowerLimit":"2.46","upperLimit":"23.10","value":"17.63"},{"comment":"Insufficient number of events to calculate median and upper limit of the CI using the K-M method.","groupId":"OG005","lowerLimit":"2.69","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"description":"DOR is from first response (complete response (CR), CR unconfirmed (CRu) or partial response (PR)) to progression (PD) or death. Those without PD or death were censored at the last assessment.\n\nCR via PET-CT: Lymph/extralymph: Score 1/2/3a w/w-out resid mass, no new lesions, No FDG-avid disease in bone marrow (BM) CR via CT scan: Lymph/extralymph: Target/nodal ≤ 1.5 cm, no new lesions, normal BM CR Cohort 5: No contrast enhance, no corticosteroid, normal eye exam, neg CSF cytology CRu Cohort 5: No contrast enhance, min abnorm, normal eye exam, neg CSF cytology PR via PET-CT: Lymph/extralymph: Score 4/5b, red uptake, no new lesions, resid uptake incr, reduced in BM PR via CT scan: Lymph/extralymph: 50% decr in sum of diam ≤ 6 target/extranodal, no new/nonmeasured lesions, Organ enlarge: Spleen decr \\> 50% PR Cohort 5: 50% decr in enhancing tumor, no contrast enhance, Eye exam: Minor abnorm, decr in vitreous cells/retinal infiltrate, negative, persist or suspic CSF cytology.","dispersionType":"95% Confidence Interval","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG003","title":"Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG004","title":"Cohort 5: Primary Central Nervous System Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG005","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"paramType":"MEDIAN","populationDescription":"All participants in the JCAR017 treated set who achieved a best overall response of complete response (and/ or CRu in cohort 5) or partial response/ remission.","reportingStatus":"POSTED","timeFrame":"From JCAR017 infusion until disease progression, death due to any reason, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}